Tharimmune Inc. (THAR) - Net Assets
Based on the latest financial reports, Tharimmune Inc. (THAR) has net assets worth $397.93 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($519.15 Million) and total liabilities ($121.22 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check THAR tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $397.93 Million |
| % of Total Assets | 76.65% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 14303.15 |
Tharimmune Inc. - Net Assets Trend (2019–2025)
This chart illustrates how Tharimmune Inc.'s net assets have evolved over time, based on quarterly financial data. Explore Tharimmune Inc. cash conversion from operations to assess how effectively this company generates cash.
Annual Net Assets for Tharimmune Inc. (2019–2025)
The table below shows the annual net assets of Tharimmune Inc. from 2019 to 2025. For live valuation and market cap data, see Tharimmune Inc. (THAR) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $397.93 Million | +30330.80% |
| 2024-12-31 | $1.31 Million | -85.68% |
| 2023-12-31 | $9.13 Million | +64.72% |
| 2022-12-31 | $5.54 Million | +218.33% |
| 2021-12-31 | $-4.68 Million | -26.02% |
| 2020-12-31 | $-3.72 Million | -129.17% |
| 2019-12-31 | $-1.62 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tharimmune Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7073184500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.71K | 0.00% |
| Other Components | $470.74 Million | 118.30% |
| Total Equity | $397.93 Million | 100.00% |
Tharimmune Inc. Competitors by Market Cap
The table below lists competitors of Tharimmune Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GREENLAND RESOURCES INC.
F:M0LY
|
$130.87 Million |
|
Connect Biopharma Holdings Ltd
NASDAQ:CNTB
|
$130.96 Million |
|
CB Industrial Product Holding
KLSE:7076
|
$131.00 Million |
|
Hardwyn India Limited
NSE:HARDWYN
|
$131.00 Million |
|
Avatec Co. Ltd
KQ:149950
|
$130.79 Million |
|
Bastogi S.p.A
F:BAOA
|
$130.77 Million |
|
Horizon Copper Corp.
V:HCU
|
$130.74 Million |
|
Tecogen Inc.
NYSE:TGEN
|
$130.69 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tharimmune Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,307,642 to 397,925,880, a change of 396,618,238 (30330.8%).
- Net loss of 35,916,250 reduced equity.
- New share issuances of 115,672,891 increased equity.
- Other factors increased equity by 316,861,597.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-35.92 Million | -9.03% |
| Share Issuances | $115.67 Million | +29.07% |
| Other Changes | $316.86 Million | +79.63% |
| Total Change | $- | 30330.80% |
Book Value vs Market Value Analysis
This analysis compares Tharimmune Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.27x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-59.09 | $3.31 | x |
| 2020-12-31 | $-135.41 | $3.31 | x |
| 2021-12-31 | $-154.59 | $3.31 | x |
| 2022-12-31 | $183.70 | $3.31 | x |
| 2023-12-31 | $104.92 | $3.31 | x |
| 2024-12-31 | $1.01 | $3.31 | x |
| 2025-12-31 | $12.42 | $3.31 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tharimmune Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -9.03%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.30x
- Recent ROE (-9.03%) is above the historical average (-170.96%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.36 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.05 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.74 Million |
| 2022 | -152.84% | 0.00% | 0.00x | 1.21x | $-9.03 Million |
| 2023 | -102.06% | 0.00% | 0.00x | 1.20x | $-10.23 Million |
| 2024 | -932.79% | 0.00% | 0.00x | 2.85x | $-12.33 Million |
| 2025 | -9.03% | 0.00% | 0.00x | 1.30x | $-75.71 Million |
Industry Comparison
This section compares Tharimmune Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tharimmune Inc. (THAR) | $397.93 Million | 0.00% | 0.30x | $130.84 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Tharimmune Inc.
Tharimmune, Inc. focuses on leveraging Canton Coin and supporting the Canton network to advance institutional blockchain adoption and the digitization of financial markets. It is also involved in the clinical-stage biotech research and development activities. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. w… Read more